

PROCEEDINGS

Open Access



Mesenchymal stem cells for treating ocular surface diseases

Liyun Zhang, Vivien Jane Coulson-Thomas, Tarsis Gesteira Ferreira and Winston W. Y. Kao*

Abstract

Mesenchymal stem cells (MSC) have become a promising tool for cell therapy in regenerative medicine. They are readily available, demonstrate powerful differentiation capabilities and present immunosuppressive properties that aid them in surviving from host immune rejection for its great potential use in allograft. Currently clinical trials are underway using MSC, both culture-expanded allogeneic and autologous, for the treatment of a range of diseases not treatable by conventional therapies. A vast array of studies has dedicated towards the use of MSC for treating corneal diseases with very promising outcomes. MSC have successfully differentiated into keratocytes both *in vitro* and *in vivo*, and corneal epithelial cells *in vitro*, but it is uncertain if MSC can assume corneal epithelial cells *in vivo*. However, to date few studies have unequivocally established the efficacy of MSC for treating corneal endothelial defects. Currently, the diversity in protocols of the isolation and expansion of MSC are hindering to the assessment of cell treatment ability and the further development of treatment regimens. Therefore, future studies should develop international standards for MSC isolation and characterization. In this review, we discuss recent advances in MSC for treating ocular surface diseases.

Introduction

Mesenchymal stem cells (MSC) are a group of fibroblast-like multipotent mesenchymal stromal cells [1, 2]. They were originally identified as multipotent stromal precursor cells in bone marrow by Friedenstein and his co-workers in 1970s [3–5]. The name of MSC was first introduced by Caplan in 1991 [6] who found these cells attained multipotent characteristics and could differentiate into multiple distinctive specialized cells. Since the stemness of MSC was potentially useful for treating diseases [2, 7, 8], MSC attracted the attention of many researchers. Besides from the bone marrow, MSC are also found in many other connective tissues, such as umbilical cord [9], adipose tissue [10] and corneal stroma [11, 12]. MSC have been isolated, cultured and characterized in various ways by numerous investigators, which makes it hard to compare the cell properties and the treatment outcomes obtained from different laboratories. In light of these discrepancies the Mesenchymal and Tissue Stem Cell Committee of The International Society for Cellular Therapy has suggested a minimal criteria to define the MSC: MSC are

plastic-adherent, must present a certain surface molecule profile (markers) and be able to differentiate to a characteristic tri-cell lineage, i.e., osteoblasts, adipocytes and chondrocytes *in vitro* [1, 13].

Most of MSC studies draw attention to their therapeutic efficacy, which have been extensively conducted in many body systems and organs, such as central nervous system, heart, blood, lung, liver, kidney, pancreas, joint, skin and eye, etc. [2]. The application of MSC in ocular diseases was superbly summarized in elegant reviews by Joe et al. [14] and Yao & Bai [15] and Li and Zhao [16]. The former mainly focused on the efficacy of treating retina degeneration, uveitis and glaucoma optic neuropathy, while the latter two focused on corneal reconstruction. In this review, we will summarize the characterization of MSC and discuss the advance of MSC research made in treating cornea and other ocular surface diseases, e.g., dry eye diseases.

Identification and characterization of MSC

Like many other cell types, MSC isolated from tissues are able to adhere to the plastic surface of cell culture

* Correspondence: Winston.Kao@UC.Edu
Department of Ophthalmology, University of Cincinnati, Ohio, USA

dish and propagate *in vitro*. They are fibroblast-like and express certain cell surface markers, though no single marker or a set of markers can be simply applied to define MSC. Multiple characterization tests must be performed and the combined results are used to identify the MSC thereby avoiding misclassification.

MSC immunophenotype

Immunophenotype analysis is one of the essential tests for MSC. In general, the minimum cell surface molecules that should be examined include positive markers: CD105 (endoglin), CD73 (5'-nucleotidase) and CD90 (Thy-1); and negative markers: CD45, CD34, CD14, CD11b (integrin α M chain), CD79 α , CD19 and HLA-DR surface molecules [13]. Many other markers have also been suggested to be indicative for the identification of MSC, such as the expression of CD13, CD29, CD44, CD106, CD166, and the lack of CD38, CD31 [17]. Stem cell-related transcription factors, such as Nanog, Oct-4 and Sox-2 [18], are also helpful in characterizing MSC. Fluorescence-activated cell sorting is routinely conducted to evaluate the purity of cell population.

MSC differentiation capacity

The MSC multipotent capacity was usually assessed by their multilineage differentiation into several mesenchymal tissues. The capacity of tri-cell-lineage differentiation, i.e., osteogenesis, adiposegenesis and chondrogenesis is the gold standard for identifying MSC and any cell preparation must meet this minimum requirement prior to being classified as MSC [13]. For such, MSC are cultured in a specific induction medium for 2 to 3 weeks in order to induce differentiation into the specific cell types. Thereafter, stainings for calcium, lipids and proteoglycans are performed to show whether the cells have been functionally specialized into osteocytes, adipocytes and chondrocytes, respectively. The potential of MSC for neural differentiation [17] and cardiogenesis [9] have also been used as criteria in some studies, however, this is not used as a routine method.

Others

There are other tests that may be employed for estimating the function of MSC. Colony-forming unit-fibroblast (CFU-F) assay [19] is useful to quantify the colony generation capacity of MSC. Cell growth kinetics measurement can reflect the cell expansion ability. Cytokine expression spectrum is also a means of evaluating the secretion ability of MSC. MSC have been found to secrete SCF, LIF, M-CSF, Flt-3, IL-6, GM-CSF, G-CSF, SDF-1/CXCL12 and VEGF, however, not IL-3 [17].

Characteristics of MSC from different tissues

MSC were initially isolated from the bone marrow [5, 19, 20]. Thereafter, many other tissues were found to contain MSC, such as umbilical cord [9, 21, 22], placenta [23], adipose tissue [10, 24], skeletal muscle [25, 26] and dental pulp [27]. The relatively abundant tissue sources and easy isolation procedures make MSC an excellent option of stem cells for autologous and allogeneic application in treating diseases. Studies have shown that different tissue origins provide advantages and disadvantages in terms of their future clinical application. The bone marrow was the first MSC source to be investigated and is still the most abundantly studied. However, the isolation of bone marrow MSC (BMMSC) requiring the invasive aspiration from donor greatly restricts its application. Wharton's jelly isolated from human umbilical cord is a rich source of MSC that can be easily expanded and stored in liquid nitrogen for immediate use [9]. MSC derived from the umbilical cords (UMSC) are believed to be more primitive than cells obtained from adult tissues. Moreover, umbilical cords are plentiful and usually discarded as biological waste. Recently, the adipose tissue is becoming a popular source for MSC isolation. The adipose tissue is another rich source of MSC (ATMSC) and enables auto-graft.

Whether MSC isolated from different sources present similar properties is an important question since it may determine which is most suitable for treating specific disease(s). Several comparison studies have been performed toward this objective [28–32]. Morphology and cell marker analysis to date has not identified significant differences among MSC isolated from bone marrow, umbilical cord blood (UCBMSC) and adipose tissue [28]. However, their colony generation, proliferation and differentiation capacities are not equal. For example, the colony generation frequency is different with the highest in ATMSC and lowest in UCBMSC. The proliferation capacity is the highest in UCBMSC and the lowest in BMMSC. In comparison to the BMMSC, UCBMSC have higher osteogenic ability but lower adipogenic potential [29]. ATMSC have higher chondrogenic potential than UMSC from Wharton jelly [30], but lower osteogenic potential than BMMSC [31]. Additionally, different MSCs present distinct immune modulatory capabilities [32]. ATMSC have been shown to be the most effective in inhibiting the differentiation of monocyte-derived dendritic cells when compared to BMMSC [32]. However, MSC from BM, Umbilical Wharton's jelly and AT present no differences in inhibiting phytohemagglutinin-induced T-cell proliferation. So far, it is not clear if these discrepancies provide any insight into which MSC treatment would be the most appropriate for treating various diseases.

Transdifferentiation of MSC to various corneal cell types

MSC can give rise to a variety of mesodermal cells as described above, and also have transdifferentiation ability to assume phenotypes of neural ectodermal cells and epithelial cells [33]. Furthermore, it has been shown that BMMSC could resemble limbal fibroblast cells which assist in maintaining the limbal epithelial stem cells in the limbal niche [34]. Both BMMSC and limbal fibroblasts show a highly similar gene expression profile, including CD106, CD54, CD166, CD90, CD29, CD71 and CD105. In addition, BMMSC and keratocytes all express CD13, CD29, CD44, CD56, CD73, CD90, CD105 and CD133 but not HLA-DR, CD34, CD117 and CD45 [35]. These studies suggested a possibility that MSC can be guided to differentiate towards corneal cells. Nevertheless, *in vivo* there is a lack of direct evidence to substantiate the differentiation of MSC to assume corneal epithelial cell phenotypes. Although, the differentiated cells *in vitro* could be used in corneal tissue engineering or cell replacement treatment. In Table 1, we summarize the current studies on MSC transdifferentiation towards corneal cells types (Table 1).

Corneal epithelial cells

During development, the corneal epithelium derives from the surface ectoderm [36]. Whether MSC can be

reprogrammed to cells of ectodermal lineage has been investigated. Early experiments reported that the MSC transplanted onto cornea do not transdifferentiate into epithelial cells *in vivo* [37]. In this study, human BMMSC were seeded on amniotic membrane and sutured on the chemically injured rat cornea. BMMSC could survive and repress the cornea inflammation, but failed to undergo corneal epithelium differentiation determined by CK3 expression [37]. However, a later study carried out in rabbits inclined to draw a positive conclusion [38]. BrdU labelled BMMSC were placed on fibrin gels and transplanted onto the alkali burned cornea. These BrdU positive cells participated in the cornea healing and were found to express CK3, implicating BMMSC differentiated into corneal epithelial cells.

The outcome of many *in vitro* experiments supported the idea that MSC are able to assume cornea epithelial cell phenotype under certain conditions, however to date *in vivo* data has shown contradictory results. The first *in vitro* experiment described was performed by co-culturing rabbit BMMSC with corneal limbal stem cells (LSCs) or LSC conditioned medium [38]. The BMMSC were found to change morphology from fibroblast-like to the broad and flattened epithelial shape in both culture systems. The immunofluorescence staining and flow

Table 1 Summary of the studies on MSC differentiating into corneal cells

Cornea cell Differentiation	MSC type	<i>In vitro</i>		<i>In vivo</i>		Reference
		Method	Differentiation test	Method	Differentiation test	
Epithelium	Human BMMSC	No	No	Rat alkali burn model received BMMSC on AM	Human Krt3 (-); human keratin-pan (-)	[37]
	Rabbit BMMSC	Coculture with Rab-LSC or Rab-LSC conditioned medium	Krt3 (+)	Rabbit alkali burn model received BMMSCs on fibrin gel	Krt3 (+)	[38]
	Rat BMMSC	Coculture with rat corneal stromal cell	Krt12 (+)	Rat alkali burn model received induced MSCs on AM	Clinical assessment; Krt12 (+)	[39]
	Human ATMSC	Coculture with basal culture medium conditioned with human corneal epithelial cells	Krt3 (+); Krt12 (+)	No	No	[40]
	Human BMMSC	Sphere culture treated with RA, BMP4 and EGF followed by the cell dissociation and Matrigel culture	Krt3 (+); Krt12 (+); Krt8(+); Transepithelial Electrical Resistance test	No	No	[41]
Keratocyte	Human UMSC	No	No	<i>Kera</i> ^{-/-} mouse and <i>lum</i> ^{-/-} mouse received UMSC corneal injection	Human keratocan (+); Lumican (+); CD34 (+); ALDH3A1 (+)	[44]
	Mouse BMMSC	No	No	<i>Kera</i> ^{-/-} mouse received BMMSC corneal injection	Human keratocan (+)	[45]
	Human BMMSC	Cultured in human keratocyte conditioned medium	Human keratocan (+); Lumican (+); ALDH1A1	No	No	[46]
Endothelium	To be studied	To be studied	To be studied	To be studied	To be studied	

This table lists all the references of studies on the MSC differentiating to all corneal cell types

BMMSC bone marrow derived mesenchymal stem cell, ATMSC adipose tissue derived mesenchymal stem cell, UMSC umbilical cord derived mesenchymal stem cell, Krt3 keratin 3, Krt12 keratin 12, Krt8 keratin 8, AM amniotic membrane, Rab-LSC rabbit limbal stem cell, ALDH1A1 aldehyde dehydrogenase 1 family member A1

cytometry analysis identified transiently increased CK3 expression in BMMSC. Jiang et al. subsequently reported that corneal stromal cells also have the similar ability to induce BMMSC to become epithelial cells. They seeded these cells on amniotic membrane and transplanted them onto the cornea of limbal stem cell deficient rats. The results showed that corneal neovascularization was significantly reduced by the transplantation of epithelium equivalent seeded on amniotic membrane. It is surprising to note that UMSC-derived epithelium equivalent yielded a better outcome than that of the direct transplantation of MSC seeded on amniotic membrane. Why the differentiated epithelium is more effective in neovascularization repression and ocular surface reconstruction deserves further investigation [39]. After co-culture with corneal stromal cells, ATMSC exhibited epithelial cell morphology and expressed the corneal epithelial cell marker CK12. Furthermore, the authors examined if the differentiated cells presented corneal epithelial cell biological function. Recently, adipose tissue derived ATMSC were shown to attain the ability to differentiate into the corneal epithelium. After culture in corneal epithelial cell conditioned medium for 15 days, ATMSC switched their morphology to epithelial-like and up-regulated Krt12 expression [40]. Even though diverse groups have described the differentiation of MSC into corneal epithelial cells, the precise mechanism remains elusive.

A recent investigation has revealed a few factors which may contribute to the MSC transdifferentiation. In the study by Katikireddy et al. [41], BMMSC were induced to assume ectodermal cell types by culturing in 3-dimensional spheres in medium containing retinoic acid (RA), bone morphogenetic protein-4 (BMP-4) and epidermal growth factor (EGF). The expression of p63 and CK8 of mRNAs were measured to indicate successful transdifferentiation. Moreover, it was found that MSC that are positive for stage-specific embryonic antigen-4 (SSEA4), an early embryonic stem cell marker [42], have higher potential to differentiate into corneal epithelial cells than SSEA4 negative MSC. The SSEA4+ MSC expressed higher levels of stem cell markers, such as Sox2, Oct4, Nanog, Rex1, ABCG2 and TRA-1-60, and can be further induced to present epithelial cell morphology and express corneal epithelium specific molecules, i.e., CK3 and CK12. The epithelium barrier integrity test, trans-epithelial electrical resistance (TER), showed the cells induced from SSEA4+ MSC present a 2-fold increase in barrier integrity than SSEA4- cells. However, they did not get to the normal TER range of corneal epithelial cells. Certainly, further optimization of the induction conditions and a longer follow up may help to confirm the possibility of obtaining functional epithelium from MSC.

Corneal keratocyte

Keratocytes are derived from the periocular mesenchyme cells of neural crest origin [43]. Successful differentiation of umbilical and bone marrow MSC into keratocytes was performed in animal studies [44, 45]. In these experiments, DiI-labeled BMMSC and UMSC were transplanted into mouse cornea stroma under disease conditions. One to two weeks after the surgery, MSC became dendritic and expressed keratocyte specific proteins, KS-keratocan (keratan sulfate keratocan) and KS-lumican.

In vitro differentiation study further confirmed the *in vivo* result [46]. When BMMSC were cultured on amniotic membrane nourished with keratocyte-conditioned medium, they quickly exhibited dendritic cell shape, within 24 h. Moreover, they produced keratocan, lumican and aldehyde dehydrogenase 1 family member A1 (ALDH1A1). It was thought that some secreted factors from the keratocytes were essential for MSC differentiation to corneal stromal cells. However, no critical factor that promotes such cell fate change was identified in this study.

Corneal endothelial cells

Only two previous studies were related to the potential of umbilical mesenchymal stem cells and bone marrow mesenchymal stem cells in differentiation to assume the corneal endothelial cell phenotypes, Joyce and coworkers showed that hUMSC could adhere to the denuded corneal endothelium and assume corneal endothelial cell like phenotypes in an *ex vivo* culture model [47]. Liu and Zhao showed that in a rabbit model autologous BMMSC transplanted on denuded corneal endothelium became irregular in shape similar to corneal endothelial cell [48]. However, the characteristics and functions of transplanted UMSC and BMMSC were not rigorously examined.

Therapeutic application of MSC

The application of MSC for treating various dysfunctions in different systems has been extensively studied and reviewed [2, 49, 50], including applications in the eye [14]. Currently, there are about 200 ongoing clinical trials registered in the National Institute of Health public database <http://clinicaltrials.gov>. The treatments cover a wide variety of diseases, such as bone/cartilage diseases, immune/autoimmune disorders, heart diseases, gastrointestinal diseases, neurodegeneration and diabetes. Relatively few MSC clinical trials have focused on ocular diseases. However, many animal studies have been dedicated towards exploring the therapeutic potential of MSC for treating retinopathy, uveitis, glaucoma and ocular surface disorders [14]. Cornea is an immune privileged tissue and its external location and transparency allows easy

assessment facilitating the evaluation of the therapeutic efficacy in live animal after MSC transplantation making it a valuable model for MSC studies. Our lab and other labs have reported that MSC transplantation could treat both congenitally diseased corneas and chemically damaged corneas (Table 2).

Animal studies

a. Congenital corneal diseases

Lumican null mice

Lumican (Lum) is a member of keratan sulfate proteoglycans which belongs to the small leucine-rich proteoglycan family [51]. It is expressed as a glycoprotein in most connective tissues, while the cornea presents the proteoglycan form, containing KS side chains. KS-Lum is primarily synthesized by keratocytes in corneal stroma and plays a major role in maintaining the corneal transparency by regulating the collagen fibrils assembly. The *Lum*^{-/-} mice present thin and opaque corneas due to the irregularly spaced and thickened collagen fibrils which results from the lack of keratan sulfate proteoglycans (KSPG) [44, 52, 53]. The phenotype displayed by these mice serves as a model for general congenital disorders which involve corneal opacities due to irregularities in collagen arrangement.

Our group found that human UMSC were able to effectively treat the corneal opacity of these mice [44]. In this study, both human UMSC and umbilical cord-derived hematopoietic stem cells (UHSC) were intrastromally transplanted into the *Lum*^{-/-} mouse corneas. Only UMSC but not UHSC transplantation improved the corneal transparency. The cornea thickness increased and the collagen fibers were re-organization enabling the corneas to become transparent. The UMSC presented reduced proliferation after transplantation and morphologically resembled the dendritic keratocyte. Moreover, they expressed keratocyte specific proteins, such as keratan

sulfate proteoglycans, KS-keratocan and KS-lumican. Follow-up observations showed that injected UMSC which were labeled with DiI were present in the cornea for at least 3 months. The relatively long-term survival of xenografted UMSC was supposedly made possible by the immune modulatory ability of the MSC. This was supported by the immunostaining results in which less infiltration of leukocytes and macrophages were seen in UMSC transplanted corneas when compared to those transplanted with UHSC.

Mucopolysaccharidosis type VII (MPS VII) mice

MPS VII, also known as Sly syndrome, is a lysosomal storage disease. It is an autosomal recessive inherited disease caused by a mutation in the *GUSB* gene coding β -glucuronidase [54–56]. The deficiency of the β -glucuronidase enzyme impedes the catabolism of heparan sulfate, dermatan sulfate and chondroitin sulfate at the glucuronic acid residues leading to the accumulation of glycosaminoglycans (GAGs) in lysosomes, which affects a multiple tissues and organs, such as the brain, bone and eye. The MPS VII mouse corneas exhibit a cloudy appearance. Our group showed that UMSC transplantation significantly reduced the cornea opacity [57]. The total GAG content in treated corneas decreased approximately 30 %, when compared to the untreated corneas, reaching levels similar to the littermate control mice. The lysosomal-associated membrane protein 2 (LAMP2) staining manifested that the number and size of lysosomes in keratocytes drastically decreased throughout the treated corneas when compared to the untreated littermate controls. This study unveiled that UMSC were able to secrete exosomes which spread throughout the entire cornea and were up-taken by both host keratocytes and endothelial cells. These observations strongly indicated that the intercellular trafficking between UMSC and host cells contributed to the catabolism of GAG enabling lysosomal recycling in the diseased cornea. It is very likely that these vesicles carry endoglycosidases which enable

Table 2 Summary of the studies on MSC in treating corneal diseases

Cornea anomalies		Species	Application	Reference
Inherited cornea anomalies	Lumican null	Mouse	Intrastromal injection	[44]
	MPS IIV	Mouse	Intrastromal injection	[57]
Cornea Chemical burn		Mouse	Intrastromal injection	[58]
		Rat	Cornea surface transplantation	[37]
		Rat	Topical application	[59]
		Rat	Subconjunctival injection	[60]
		Rabbit, rat, mouse	Systematically application	[63–65]
Persistent cornea epithelium defect		Human	Cornea leision injection	[66]
GVH dry eye		Human	Blood infusion	[67]

This table summarizes the current research on MSC treating corneal diseases both in animal and human. The MSC application methods are specified
PMS IIV Mucopolysaccharidosis type VII

the turnover of the accumulated GAGs in host keratocytes, endothelial cells, and extracellular matrix.

b. Chemical burn

Corneal chemical and thermal burns are common eye traumas. The injured area and the severity can vary a lot with damage ranging from only limited on the ocular surface causing epithelium wounds, corneal stroma opacity and/or neovascularization, to much more severe which penetrates into the eye leading to persistent intraocular inflammation and destructions. In the corneal alkali burn rat model, human BMMSC were seeded onto an amniotic membrane which was then sutured on the cornea surface [37]. This treatment regimen successfully aided corneal epithelium regeneration, and at the same time suppressed the corneal neovascularization. The rats vision was improved as determined by behavioral assay. The immunostaining for cell markers and cytokines indicated that the treatment efficacy of MSC was due to their ability to suppress inflammation. MSC survived on the cornea surface for at least four weeks after the transplantation. Nonetheless, they did not assume corneal epithelial cell phenotype.

We have recently shown that UMSC transplanted into the alkali burnt mouse cornea suppress the immune response enabling recovery of a transparent cornea within 2 weeks, while control mice present severe inflammatory response as this same time-frame [56]. Moreover, we further unveiled that the UMSC secrete a specific glycocalyx which traps and suppresses the immune cells [58].

In another study of ethanol burned rat corneas, it was found that both MSC and MSC conditioned media applied 3-times per day were able to reduce the cornea inflammation and neovascularization, in turn increased the corneal transparency [59]. The inflammatory response assay showed a reduction of CD4⁺ T cells infiltration into the treated cornea accompanied by reduced secretion of pro-inflammatory cytokines, e.g., IL-2 and IFN- γ , while anti-inflammatory cytokines, e.g., IL-10 and TNF- β increased. This study suggested that the anti-inflammatory and anti-angiogenic effect of MSC most likely relies on their paracrine capacity. This idea was further supported by another experiment of a rat alkali burn model in that the subconjunctival injected MSC promoted cornea wound healing via attenuated inflammation and neovascularization [60]. The results suggested that it is not necessary to transplant MSC in the wounded area to achieve therapeutic effects.

In a study involving chemical burn in rabbit corneas, Rb-MSCs were suspended in fibrin gels and transplanted onto injured rabbit corneas, restoring the corneal surface [15, 38]. These MSC showed expression of cytokeratin 3 (CK3), a corneal epithelial-specific marker. Another

in vivo study confirmed that MSC have the ability to differentiate into corneal epithelial cells in experimental limbal stem cell deficiency rabbit model, maintaining stem cell characteristics, while some even transdifferentiated into epithelial progenitor cells [61]. Human MSC (hMSC) are also able to survive and migrate into the cornea stroma after transplantation onto the surface of the alkali-burned rabbit cornea, not only differentiating into corneal epithelium cells but differentiating into cells other than epithelia [62].

Furthermore, several groups have shown that the therapeutic effect of MSC in cornea could also be obtained via systemic administration. After the corneal injury, the intravenous or intraperitoneal infusion of MSC all increased the corneal transparency and suppressed the inflammation. These observations were obtained in several experimental animal models, such as rabbit, rat and mouse. However, the opinions on whether the introduced MSC could engraft into the cornea are inconsistent. For example, some studies showed the systemically transplanted cells could home to cornea, since the labeled MSC injected through vein was eventually seen in the injured cornea [63–65]. In contrast, other studies presented evidence that injected MSC could not be detected in cornea, even when using sensitive techniques such as quantitative PCR [64]. Instead, they proposed that MSC treatment effect might be derived from the TSG-6 secreted by MSC, and TSG-6 systematically or locally administration can reciprocate the MSC therapeutic effect.

Clinical trials: treatment of dry eyes with MSC

The application of MSC in treating cornea diseases has made great strides in animal studies. However, few human clinical trials have been conducted due to the safety concerns. So far, only two clinical studies of MSC in treating ocular surface diseases have been performed with very promising results.

One was a case report in which the ATMSC were found to facilitate the epithelial healing in one persistent sterile corneal epithelial defect patient [66]. This patient had keratoconus and got corneal cross-linking treatment one year before an injury occurred in his eye. After the accident, the cornea epithelial cells failed to regenerate, and accompanied by the underlying stromal opacification and mild conjunctival inflammation. He received many medications including antibiotic, anti-herpetic, anti-fungal treatments, artificial tears and soft contact lens within 7 weeks after the injury. None of these treatments showed any signs of improvement. Then, he consented to try MSC transplantation. Autologous ATMSC were topically injected into the bottom of cornea ulcer. Eleven days after the injection, the area of corneal epithelial defect started to regress. And one month later, the cornea was completely healed. This case is the first report of autologous

MSC application in human cornea. The result is consistent with animal studies that revealed MSC do have the ability of facilitating corneal epithelial cell regeneration.

A clinical trial of MSC was designed to treat dry eye disorder associated with chronic graft-versus-host disease (GVHD) [67], which is a common complication of the allogeneic bone marrow transplantation [68]. The GVHD can damage multiple organs and tissues, such as skin, eye, liver, lung and immune system. About half of the patients have dry eye problems after receiving hematopoietic stem cell transplantation [69–73]. MSC have been successfully used to treat severe cases of GVHD in humans [74, 75]. Their treatment efficacy for dry eye was observed by Weng et al. [67, 76]. They recruited 22 GVHD-related dry eye patients and gave them intravenous injection of MSC. Twelve out of 22 patients presented improved clinical symptoms as judged by the dry eye scores, the ocular surface index and the Schirmer test results. The peripheral blood test found the number of CD8⁺CD28⁻ T cells, a subgroup of regulatory T (T_{reg}) cells, was higher in patients who responded to MSC treatment than those patients showed little improvement. Thus, it was proposed that MSC may enhance the generation of CD8⁺CD28⁻ T_{reg} cells that further modulate the balance of Th1 and Th2 cell populations in the immune response involved in GVHD [77].

In a another study, a one-week topical application of MSCs lead to an increase in aqueous tear volume and improvement in ocular surface evaluation tests in a dry eye model in rats [78]. These authors demonstrated that topical application of MSCs can decrease inflammation by their anti-inflammatory effects, increase aqueous tear volume and improve ocular surface evaluation tests in a BAC induced dry eye model in rats.

Mechanism of MSC therapy

MSC have shown treatment efficacy for different types of diseases. The molecular mechanisms of their treatment success remains largely unclear. Several possible mechanisms have been proposed.

Cell replacement

The classical cell replacement therapy uses MSC to functionally reconstitute the hematopoietic microenvironment of bone marrow [79]. When MSC is transplanted into bone marrow of non-obese diabetic/severe combined immunodeficiency mice, they differentiate into multiple cell types essential for keeping hematopoietic cells primitive in terms of function and phenotype.

In congenital cornea diseases, the therapeutic effect of MSC is at least partially attributed to either the supplementation or substitution of corneal cells. In *Lum*^{-/-} cornea [44], the introduced MSC assumed keratocytes morphology and function. The transplanted UMSC laid

down the essential structural components in cornea stroma such as, lumican and keratocan, which helped to re-organized the collagen fibrils leading to normal corneal thickness and transparency. Similarly, MSC transplanted into MPS VII mice cornea also presented keratocytes phenotype [57]. The transplanted MSC provided the functional metabolic enzymes that allowed the degradation of the accumulated GAGs thereby assisting in the lysosome recycling.

Paracrine competence

MSC secrete several signalling molecules, such as neurotrophic factors, growth factors or cytokines, which can diffuse in the local tissue environment and interact with the surrounding cells. MSC paracrine ability has been studied in many systems, such as hepatic and central nervous system [80–85].

In the cornea, MSC paracrine effects have been well demonstrated by their anti-inflammation and anti-angiogenesis functions in cornea chemical burn models. Under the injured condition, the transplanted MSC could produce a set of signalling effectors that resulted in a decrease of host pro-inflammatory cytokines, e.g., IL-2, MMP2, IFN γ and increase of anti-inflammatory cytokine, e.g., IL-6, IL-10, and growth factor, e.g., TGF β [37, 59]. These factors then initiate the downstream signalling transduction and finally repress inflammation. Moreover, MSC also change the levels of many angiogenesis-associated factors in cornea, such as TSP-1, MMP-2 and VEGF, which in turn reduce the neovascularisation [59]. Moreover, our recent study demonstrated that a rich specific glycocalyx secreted by UMSC can trap and inhibit inflammatory cells [56].

Exosome-mediated intercellular trafficking

Exosomes are microvesicles with diameter about 40 to 100 nm, which originate from the fusion of intracellular multivesicular bodies (MVBs) with cell membrane and are released into the extracellular spaces [86]. They are composed of a bi-layered lipid membrane, proteins, mRNA and miRNA [86, 87]. Exosomes are secreted by many types of cells including MSC [88–90]. The MSC-derived exosomes have been reported to have many important biological functions, such as treating cardiovascular disease [89], ameliorating renal oxidative stress [91] and suppressing VEGF expression in breast cancer cells [92].

Our group detected the exosomes released by the transplanted UMSC in the diseased cornea of MPS VII mice, and also found that these exosomes were able to enter into host corneal keratocytes and endothelial cells [57]. The *in vitro* experiments further discovered that UMSC-secreted exosomes assisted in the recycling process of accumulated GAGs in the lysosomes in MPS VII cells.

This study proposed a new mechanism of MSC in treating corneal disease.

Immunomodulatory ability

One of many amazing functions of MSC is that it can regulate the recipient immune response by modulating the maturation and the function of multiple immune cells, such as myeloid dendritic cells [93], natural killer (NK) cells [94], T cells [95–98] and B cells [99, 100] and macrophages. One good example in eye for this immunomodulatory ability is the treatment effect for GVHD-associated dry eye patients [67]. In patients with treatment effect, the level of CD8⁺CD28⁻ T cells was observed higher than those patients without effect. The *in vitro* co-culture experiment showed that MSC could facilitate CD8⁺ cell to undergo CD8⁺CD28⁻ T_{reg} cell fate, a cell type that may regulate the balance of T-helper 1/T helper 2 activity.

Tissue homing capacity for treating congenital

MSC administrated systemically can home into a wide range of tissues and exist *in situ* for a relatively long period of time. A non-human primate study reported that the infused GFP labelled MSC was detected in 16 distinct tissues with different cell quantities by quantitative PCR at even 21 months after the infusion [101]. Moreover, the amount of MSC in tissues is higher in animals that received lethal whole body irradiation and hematopoietic support than in the non-conditioned animal. It seems that injury facilitates MSC infiltration into tissues.

A similar observation was made for cornea wound healing process [65]. Q-dot or GFP labelled MSC was intravenously injected into mice that received thermal cauterization in one side of the cornea. MSC homed to the injured cornea but not the naïve contralateral uninjured cornea. This led to a faster corneal epithelium recovery than the untransplanted control mice.

Future research direction

MSC isolated from different tissues by different techniques may possess different levels of abilities which may directly impact their efficacies on treating various diseases. Thus, optimizing the isolation and propagation procedure is critical to make a more reproducible and homogenous cell preparation. Moreover, since the current minimal criteria to define MSC proposed by The International Society for Cellular Therapy is not able to fully indicate the competence of MSC on treating disease, a therapeutic test is required evaluate the cell quality.

So far, the precise mechanism by which MSC treat diseases remains elusive. Further investigations of how MSC modulate the immune response, communicate with host cells and become resident cells will help to delineate the

molecular and cellular basis of utilizing MSC to treat diseases.

As for cell replacement therapy in the cornea, one interesting research direction could be inducing MSC to differentiate into corneal endothelial cells *in vitro*, and then performing the corneal endothelial transplant. It is known that cornea endothelial cells are critical in maintaining cornea transparency. Once damaged in adult humans, the endothelial cells are not able to regenerate [102]. Clinically, corneal endothelial keratoplasty has been performed successfully to provide the functional endothelium. However, this surgery is still limited by the availability of suitable donor corneas. If MSC could be guided to transdifferentiate into endothelial cell, it would provide a plentiful source of endothelium graft in lieu of the whole cornea suitable for transplant.

As described above, the transplanted MSC can survive in the cornea and secretes factors to improve the acute conditions of traumatized cornea. However, how long MSC can provide the regulatory effect is not known. Once the MSC engages into the cornea and becomes the resident cells of the tissue, it may lose the stem cell characteristics and fail to provide further protection to the host. In order to maintain sustainable expression of the certain effectors, a genetic modification of MSC could be a meaningful research direction. Several gene engineering studies have demonstrated that MSC secreting erythropoietin (EPO) [103] or brain-derived neurotrophic factor [104, 105] provided persistent neural protective effect in retina degeneration models. Since MSC can live in the tissue for relatively long time, it can be an excellent gene delivery system for treating congenital mutation of metabolic enzymes to do the treatment.

Another issue is the safety of using MSC. It remains uncertain whether MSC have long term adverse effects on the immune system and whether there is a possibility of inducing tumorigenesis. The future studies may need to clarify these concerns.

Compared to systemic administration, local MSC transplantation may have fewer side effects, especially for corneal applications. The avascular nature of the cornea makes it an immunologically privileged tissue [106] and transplanted cells tend to have high survival rates and reduced host versus graft disease. Moreover, the ocular surface location eases the *in vivo* observation making the cornea a very attractive model for studying the application of MSC both in animal models and humans.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LZ: contributed to the conception, design and drafting of this review. VJCT: contributed to the conception, design and drafting of this review. TGF: contributed to the conception, design and drafting of this review. WWYK:

contributed to the conception, revision and final approval of this review. All authors read and approved the final manuscript.

Acknowledgements

The study is supported by NIH/NEI grant EY# 1R01EY021768, Research to Prevent Blindness, unrestricted departmental grant to Dr. James J. Augsburger, Ohio Lions Eye Research Foundation.

Declaration

The publication cost of this manuscript was funded by the Department of Ophthalmology, Wakayama Medical University, Wakayama, Japan. This article has been published as part of BMC Ophthalmology Volume 15 Supplement 1, 2015: Proceedings of the 2nd Ocular Cell Biology Symposium at Wakayama. The full contents of the supplement are available online at <http://www.biomedcentral.com/bmcophthalmol/supplements>.

Published: 17 December 2015

References

- Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy*. 2005;7(5):393–5.
- Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. *Nat Rev Immunol*. 2008;8(9):726–36.
- Friedenstein AJ, Chailakhyan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet*. 1970;3(4):393–403.
- Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. *Transplantation*. 1974;17(4):331–40.
- Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp Hematol*. 1976;4(5):267–74.
- Caplan AL. Mesenchymal stem cells. *J Orthop Res*. 1991;9(5):641–50.
- Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. *Cell Stem Cell*. 2008;2(4):313–9.
- Caplan AL. Why are MSCs therapeutic? New data: new insight. *J Pathol*. 2009;217(2):318–24.
- Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. *Stem Cells*. 2004;22(7):1330–7.
- Rodriguez AM, Elabd C, Amri EZ, Ailhaud G, Dani C. The human adipose tissue is a source of multipotent stem cells. *Biochimie*. 2005;87(1):125–8.
- Du L, Lyle CS, Chambers TC. Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. *Oncogene*. 2005;24(1):107–17.
- Branch MJ, Hashmani K, Dhilon P, Jones DR, Dua HS, Hopkinson A. Mesenchymal stem cells in the human corneal limbal stroma. *Invest Ophthalmol Vis Sci*. 2012;53(9):5109–16.
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8(4):315–7.
- Joe AW, Gregory-Evans K. Mesenchymal stem cells and potential applications in treating ocular disease. *Curr Eye Res*. 2010;35(11):941–52.
- Yao L, Bai H. Review: mesenchymal stem cells and corneal reconstruction. *Mol Vis*. 2013;19:2237–43.
- Li F, Zhao SZ. Mesenchymal stem cells: Potential role in corneal wound repair and transplantation. *World J Stem Cells*. 2014;6(3):296–304.
- Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. *Haematologica*. 2006;91(8):1017–26.
- Zhang H, Zhang B, Tao Y, Cheng M, Hu J, Xu M, et al. Isolation and characterization of mesenchymal stem cells from whole human umbilical cord applying a single enzyme approach. *Cell Biochem Funct*. 2012;30(8):643–9.
- Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiarieri D, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. *Blood*. 1980;56(2):289–301.
- Kuznetsov SA, Krebsbach PH, Satomura K, Kerr J, Riminucci M, Benayahu D, et al. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. *J Bone Miner Res*. 1997;12(9):1335–47.
- Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. *Stem Cells*. 2005;23(2):220–9.
- Kim JW, Kim SY, Park SY, Kim YM, Kim JM, Lee MH, et al. Mesenchymal progenitor cells in the human umbilical cord. *Ann Hematol*. 2004;83(12):733–8.
- Takahashi K, Igura K, Zhang X, Mitsuru A, Takahashi TA. Effects of osteogenic induction on mesenchymal cells from fetal and maternal parts of human placenta. *Cell Transplant*. 2004;13(4):337–41.
- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng*. 2001;7(2):211–28.
- Williams JT, Southerland SS, Souza J, Calcutt AF, Cartledge RG. Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. *Am Surg*. 1999;65(1):22–6.
- Lee JY, Qu-Petersen Z, Cao B, Kimura S, Jankowski R, Cummins J, et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. *J Cell Biol*. 2000;150(5):1085–100.
- Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. *Proc Natl Acad Sci U S A*. 2000;97(25):13625–30.
- Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells*. 2006;24(5):1294–301.
- Chang YJ, Shih DT, Tseng CP, Hsieh TB, Lee DC, Hwang SM. Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. *Stem Cells*. 2006;24(3):679–85.
- Hildner F, Wolbank S, Redl H, van Griensven M, Peterbauer A. How chondrogenic are human umbilical cord matrix cells? A comparison to adipose-derived stem cells. *J Tissue Eng Regen Med*. 2010;4(3):242–5.
- Niemeyer P, Fechner K, Milz S, Richter W, Suedkamp NP, Mehlhorn AT, et al. Comparison of mesenchymal stem cells from bone marrow and adipose tissue for bone regeneration in a critical size defect of the sheep tibia and the influence of platelet-rich plasma. *Biomaterials*. 2010;31(13):3572–9.
- Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. *Cell Immunol*. 2009;259(2):150–6.
- Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. *Stem Cells*. 2007;25(11):2896–902.
- Polisetty N, Fatima A, Madhira SL, Sangwan VS, Vemuganti GK. Mesenchymal cells from limbal stroma of human eye. *Mol Vis*. 2008;14:431–42.
- Choong PF, Mok PL, Cheong SK, Then KY. Mesenchymal stromal cell-like characteristics of corneal keratocytes. *Cytotherapy*. 2007;9(3):252–8.
- Graw J. Eye development. *Curr Top Dev Biol*. 2010;90:343–86.
- Ma Y, Xu Y, Xiao Z, Yang W, Zhang C, Song E, et al. Reconstruction of chemically burned rat corneal surface by bone marrow-derived human mesenchymal stem cells. *Stem Cells*. 2006;24(2):315–21.
- Gu S, Xing C, Han J, Tso MO, Hong J. Differentiation of rabbit bone marrow mesenchymal stem cells into corneal epithelial cells in vivo and ex vivo. *Mol Vis*. 2009;15:99–107.
- Jiang TS, Cai L, Ji WY, Hui YN, Wang YS, Hu D, et al. Reconstruction of the corneal epithelium with induced marrow mesenchymal stem cells in rats. *Mol Vis*. 2010;16:1304–16.
- Nieto-Miguel T, Galindo S, Reinoso R, Corell A, Martino M, Perez-Simon JA, et al. In vitro simulation of corneal epithelium microenvironment induces a corneal epithelial-like cell phenotype from human adipose tissue mesenchymal stem cells. *Curr Eye Res*. 2013;38(9):933–44.
- Katikireddy KR, Dana R, Jurkunas UV. Differentiation potential of limbal fibroblasts and bone marrow mesenchymal stem cells to corneal epithelial cells. *Stem Cells*. 2014;32(3):717–29.
- Henderson JK, Draper JS, Baillie HS, Fishel S, Thomson JA, Moore H, et al. Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. *Stem Cells*. 2002;20(4):329–37.

43. Quantock AJ, Young RD. Development of the corneal stroma, and the collagen-proteoglycan associations that help define its structure and function. *Dev Dyn*. 2008;237(10):2607–21.
44. Liu H, Zhang J, Liu CY, Wang LJ, Sieber M, Chang J, et al. Cell therapy of congenital corneal diseases with umbilical mesenchymal stem cells: lumican null mice. *PLoS ONE*. 2010;5(5):e10707.
45. Liu H, Zhang J, Liu CY, Hayashi Y, Kao WW. Bone marrow mesenchymal stem cells can differentiate and assume corneal keratocyte phenotype. *J Cell Mol Med*. 2012;16(5):1114–24.
46. Park SH, Kim KW, Chun YS, Kim JC. Human mesenchymal stem cells differentiate into keratocyte-like cells in keratocyte-conditioned medium. *Exp Eye Res*. 2012;101:16–26.
47. Joyce NC, Harris DL, Markov V, Zhang Z, Saitta B. Potential of human umbilical cord blood mesenchymal stem cells to heal damaged corneal endothelium. *Mol Vis*. 2012;18:547–64.
48. Liu XW, Zhao JL. [Transplantation of autologous bone marrow mesenchymal stem cells for the treatment of corneal endothelium damages in rabbits]. *Zhonghua Yan Ke Za Zhi*. 2007;43(6):540–5.
49. Krampera M, Franchini M, Pizzolo G, Aprili G. Mesenchymal stem cells: from biology to clinical use. *Blood Transfus*. 2007;5(3):120–9.
50. Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. *BMC Med*. 2011;9:52.
51. Kao WW. Ocular surface tissue morphogenesis in normal and disease States revealed by genetically modified mice. *Cornea*. 2006;25 Suppl 1:S7–S19.
52. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. *J Cell Biol*. 1998;141(5):1277–86.
53. Saika S. TGFbeta pathobiology in the eye. *Lab Invest*. 2006;86(2):106–15.
54. Tomatsu S, Fukuda S, Sukegawa K, Ikedo Y, Yamada S, Yamada Y, et al. Mucopolysaccharidosis type VII: characterization of mutations and molecular heterogeneity. *Am J Hum Genet*. 1991;48(1):89–96.
55. Vervoort R, Buist NR, Kleijer WJ, Wevers R, Fryns JP, Liebaers I, et al. Molecular analysis of the beta-glucuronidase gene: novel mutations in mucopolysaccharidosis type VII and heterogeneity of the polyadenylation region. *Hum Genet*. 1997;99(4):462–8.
56. Tomatsu S, Montano AM, Dung VC, Grubb JH, Sly WS. Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome). *Hum Mutat*. 2009;30(4):511–9.
57. Coulson-Thomas VJ, Caterson B, Kao WW. Transplantation of human umbilical mesenchymal stem cells cures the corneal defects of mucopolysaccharidosis VII mice. *Stem Cells*. 2013;31(10):2116–26.
58. Coulson-Thomas VJ, Gesteira TF, Hascall V, Kao W. Umbilical cord mesenchymal stem cells suppress host rejection: the role of the glycoalyx. *J Biol Chem*. 2014;289(34):23465–81.
59. Oh JY, Kim MK, Shin MS, Lee HJ, Ko JH, Wee WR, et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. *Stem Cells*. 2008;26(4):1047–55.
60. Yao L, Li ZR, Su WR, Li YP, Lin ML, Zhang WX, et al. Role of mesenchymal stem cells on cornea wound healing induced by acute alkali burn. *PLoS One*. 2012;7(2):e30842.
61. Reinschagen H, Auw-Haedrich C, Sorg RV, Boehringer D, Eberwein P, Schwartzkopff J, et al. Corneal surface reconstruction using adult mesenchymal stem cells in experimental limbal stem cell deficiency in rabbits. *Acta Ophthalmol*. 2011;89(8):741–8.
62. Guo T, Wang W, Zhang J, Chen X, Li BZ, Li LS. [Experimental study on repairing damage of corneal surface by mesenchymal stem cells transplantation]. *Zhonghua Yan Ke Za Zhi*. 2006;42(3):246–50.
63. Ye J, Yao K, Kim JC. Mesenchymal stem cell transplantation in a rabbit corneal alkali burn model: engraftment and involvement in wound healing. *Eye (Lond)*. 2006;20(4):482–90.
64. Roddy GW, Oh JY, Lee RH, Bartosh TJ, Ylostalo J, Coble K, et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. *Stem Cells*. 2011;29(10):1572–9.
65. Lan Y, Kodati S, Lee HS, Omoto M, Jin Y, Chauhan SK. Kinetics and function of mesenchymal stem cells in corneal injury. *Invest Ophthalmol Vis Sci*. 2012;53(7):3638–44.
66. Agorogiannis GI, Alexaki VI, Castana O, Kymionis GD. Topical application of autologous adipose-derived mesenchymal stem cells (MSCs) for persistent sterile corneal epithelial defect. *Albrecht Von Graefes Arch Klin Exp Ophthalmol*. 2012;250(3):455–7.
67. Weng J, He C, Lai P, Luo C, Guo R, Wu S, et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. *Mol Ther*. 2012;20(12):2347–54.
68. Ferrara JL, Deeg HJ. Graft-versus-host disease. *N Engl J Med*. 1991;324(10):667–74.
69. Mencucci R, Rossi Ferrini C, Bosi A, Volpe R, Guidi S, Salvi G. Ophthalmological aspects in allogeneic bone marrow transplantation: Sjogren-like syndrome in graft-versus-host disease. *Eur J Ophthalmol*. 1997;7(1):13–8.
70. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. *Cornea*. 2003;22(7 Suppl):S19–27.
71. Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M, et al. Dry eye after haematopoietic stem cell transplantation. *Br J Ophthalmol*. 1999;83(10):1125–30.
72. Sales CS, Johnston LJ, Ta CN. Long-term clinical course of dry eye in patients with chronic graft-versus-host disease referred for eye examination. *Cornea*. 2011;30(2):143–9.
73. Koch KR, Jousen AM, Huber KK. Ocular involvement in chronic graft-versus-host disease: therapeutic approaches to complicated courses. *Cornea*. 2011;30(1):107–13.
74. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet*. 2004;363(9419):1439–41.
75. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. *Leukemia*. 2007;21(8):1733–8.
76. Lee MJ, Ko AY, Ko JH, Lee HJ, Kim MK, Wee WR, et al. Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye. *Mol Ther*. 2015;23(1):139–46.
77. Nakashima H. Membranous nephropathy is developed under Th2 environment in chronic graft-versus-host disease. *Med Hypotheses*. 2007;69(4):787–91.
78. Beyazyildiz E, Pinarli FA, Beyazyildiz O, Hekimoglu ER, Acar U, Demir MN, et al. Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model. *Stem Cells Int*. 2014;2014:250230.
79. Muguruma Y, Yahata T, Miyatake H, Sato T, Uno T, Itoh J, et al. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. *Blood*. 2006;107(5):1878–87.
80. Lin N, Hu K, Chen S, Xie S, Tang Z, Lin J, et al. Nerve growth factor-mediated paracrine regulation of hepatic stellate cells by multipotent mesenchymal stromal cells. *Life Sci*. 2009;85(7–8):291–5.
81. Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. *Bone Marrow Transplant*. 2007;40(7):609–19.
82. Dasari VR, Spomar DG, Cady C, Gujrati M, Rao JS, Dinh DH. Mesenchymal stem cells from rat bone marrow downregulate caspase-3-mediated apoptotic pathway after spinal cord injury in rats. *Neurochem Res*. 2007;32(12):2080–93.
83. Karussis D, Kassis I, Kurkalli BG, Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. *J Neurol Sci*. 2008;265(1–2):131–5.
84. Slavin S, Kurkalli BG, Karussis D. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. *Clin Neurol Neurosurg*. 2008;110(9):943–6.
85. Torrente Y, Polli E. Mesenchymal stem cell transplantation for neurodegenerative diseases. *Cell Transplant*. 2008;17(10–11):1103–13.
86. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. *Traffic*. 2002;3(5):321–30.
87. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007;9(6):654–9.
88. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem*. 1987;262(19):9412–20.
89. Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. *Regen Med*. 2011;6(4):481–92.

90. Tan SS, Yin Y, Lee T, Lai RC, Yeo RW, Zhang B, Choo A, Lim SK: Therapeutic MSC exosomes are derived from lipid raft microdomains in the plasma membrane. *J Extracell Vesicles* 2013, **2**. doi: 10.3402/jev.v2i0.22614.
91. Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. *Stem Cell Res Ther.* 2013;4(2):34.
92. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. *PLoS One.* 2013;8(12):e84256.
93. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. *Blood.* 2005;105(10):4120–6.
94. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood.* 2006;107(4):1484–90.
95. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation.* 2003;75(3):389–97.
96. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood.* 2005;106(5):1755–61.
97. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. *Blood.* 2003;101(9):3722–9.
98. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. *Blood.* 2005;105(7):2821–7.
99. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. *Blood.* 2006;107(1):367–72.
100. Traggiati E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L, et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. *Stem Cells.* 2008;26(2):562–9.
101. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. *Blood.* 2003;101(8):2999–3001.
102. Mergler S, Pleyer U. The human corneal endothelium: new insights into electrophysiology and ion channels. *Prog Retin Eye Res.* 2007;26(4):359–78.
103. Guan Y, Cui L, Qu Z, Lu L, Wang F, Wu Y, et al. Subretinal transplantation of rat MSCs and erythropoietin gene modified rat MSCs for protecting and rescuing degenerative retina in rats. *Curr Mol Med.* 2013;13(9):1419–31.
104. Harper MM, Adamson L, Blits B, Bunge MB, Grozdanic SD, Sakaguchi DS. Brain-derived neurotrophic factor released from engineered mesenchymal stem cells attenuates glutamate- and hydrogen peroxide-mediated death of staurosporine-differentiated RGC-5 cells. *Exp Eye Res.* 2009;89(4):538–48.
105. Harper MM, Grozdanic SD, Blits B, Kuehn MH, Zamzow D, Buss JE, et al. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. *Invest Ophthalmol Vis Sci.* 2011;52(7):4506–15.
106. Niederkorn JY. The immune privilege of corneal grafts. *J Leukoc Biol.* 2003;74(2):167–71.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

